McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
This article was originally published in The Tan Sheet
Executive Summary
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.
You may also be interested in...
Korea Suspends J&J Subsidiary Production Of 4 OTCs
The Ministry of Food and Drug Safety orders a halt to manufacturing of five products after an investigation of GMP deviations at J&J’s Korean unit. Production of each of the products will be halted between one and five months.
Korea Suspends J&J Subsidiary Production Of 4 OTCs
The Ministry of Food and Drug Safety orders a halt to manufacturing of five products after an investigation of GMP deviations at J&J’s Korean unit. Production of each of the products will be halted between one and five months.
J&J Consumer Business Picks Up, But Analysts See Long Road
The consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.